Compare CVS Health Corp (CVS) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Oxford Lane Capital Corp — how do they compare? CVS Health Corp trades at $86.85 (market cap $112.49B), while Oxford Lane Capital Corp trades at $8.62 (market cap $829.34M). The key difference: CVS Health Corp is far larger — about 135.6× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays the higher dividend (28.37%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Oxford Lane Capital Corp for 49 Days on average.
| CVS | OXLC | |
|---|---|---|
Market Cap | $112.49B | $829.34M |
Volume | 8,467,392 | 1,709,917 |
Sector | Health | Financials |
52-Week High | $110.60 | $16.74 |
52-Week Low | $70.08 | $8.15 |
Typical Hold Time | 83 Days | 49 Days |
Enterprise Value | $174.83B | $1.22B |
Dividend Yield | 3.02% | 28.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
OXLC trades at $8.46, down 2.53% on the day, with a bearish technical outlook and negative profitability metrics. Recent earnings misses and a sharp decline in net income for 2026 highlight fundamental challenges, though the stock pays consistent dividends. Analyst sentiment is mixed, with a 50% buy rating but cautious media coverage on sustainability.
The outlook remains risky due to volatile earnings, high payout ratios, and NAV erosion. Potential exists for value investors attracted by the P/B discount and high yield, but significant headwinds in CLO market exposure and operational cash flow deficits warrant caution for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
